Glenmark USA launches Sugammadex Injection; $1.6B market

Glenmark Pharmaceuticals Inc., USA has launched Sugammadex Injection in 200 mg/2 mL and 500 mg/5 mL single-dose vials. This new product is bioequivalent and therapeutically equivalent to Merck Sharp & Dohme LLC's BRIDION® Injection. The market for the reference listed drug, BRIDION® Injection, recorded annual sales of approximately $1.6 billion for the 12-month period ending May 2026. This launch significantly enhances Glenmark's U.S. injectables portfolio, reinforcing its position in the hospital and institutional segments, and aims to improve supply reliability and access to high-quality, affordable medicines across the U.S. healthcare system.